Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs f…
Biotechnology
US, Cranbury [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Rocket Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -2.6800 | -3.075 | 0 | 0.09 | -169 | -258 | -163 | 0 | -171 | 0 | 41 | 0 |
| 2023 | -3.2200 | -3.065 | 0 | 0.99 | -219 | -253 | -213 | 0 | -230 | 0 | 58 | 0 |
| 2024 | -2.9200 | -2.901 | 0 | 7 | -245 | -243 | -252 | 0 | -259 | 0 | 71 | 0 |
| 2025 | - | -2.576 | - | 57 | - | -269 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |